Nadofaragene firadenovec - FKD Therapies
Alternative Names: AAV-IFN-apha-2b-gene-therapy-FKD-Therapies; Adenovirus-Delivered Interferon Alpha-2b; Adstiladrin; FE-999326; Instiladrin; Nadofaragene firadenovec-vncg; Nadofaragene firadenovec/Syn3; rAd-IFNα; rAd-IFNα/Syn3; SCH-209702/SCH-721015; SCH-721015; SCH-721015/SCH-209702; TR-002Latest Information Update: 14 May 2024
At a glance
- Originator Schering-Plough
- Developer Ferring Pharmaceuticals; FKD Therapies; Trizell; University of Pennsylvania
- Class Antineoplastics; IFNA2B gene therapies; Immunotherapies
- Mechanism of Action Gene transference; IFNA2B expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bladder cancer
- Phase III Malignant-mesothelioma
Most Recent Events
- 06 May 2024 Efficacy and adverse events data from phase III trial in Bladder cancer released by Ferring Pharmaceuticals
- 03 May 2024 Efficacy data from a phase II trial in Bladder cancer presented at 119th Annual Meeting of the American Urological Association (AUA-2024)
- 03 May 2024 Efficacy data from a phase III trial in Bladder cancer presented at 119th Annual Meeting of the American Urological Association (AUA-2024)